DrugPatentWatch Database Preview

Drugs in Development Information for Ladarixin

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Ladarixin?

Ladarixin is an investigational drug.

There have been 4 clinical trials for Ladarixin. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1^st 2020.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 1, Diabetes Mellitus, and [disabled in preview]. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A and [disabled in preview].

There are nine US patents protecting this investigational drug and sixty-five international patents.

Summary for Ladarixin

US Patents	9
International Patents	65
US Patent Applications	30
WIPO Patent Applications	29
Japanese Patent Applications	6
Clinical Trial Progress	Phase 1 (2020-12-01)
Vendors	10

Recent Clinical Trials for Ladarixin

Title	Sponsor	Phase
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.	Dompé Farmaceutici S.p.A	Phase 2
A Phase 3 Randomized, Controlled Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function	Dompé Farmaceutici S.p.A	Phase 3
A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers	Dompé Farmaceutici S.p.A	Phase 1

See all Ladarixin clinical trials

Clinical Trial Summary for Ladarixin

Top disease conditions for Ladarixin

Top clinical trial sponsors for Ladarixin

See all Ladarixin clinical trials

US Patents for Ladarixin

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Ladarixin		Controlled release dosage form	TRIASTEK, INC. (Nanjing, CN)
Ladarixin		Oral drug dosage forms having desired drug release profiles and uses thereof	Triastek, Inc. (Nanjing, CN)
Ladarixin		Soluble C5aR antagonists	ChemoCentryx, Inc. (Mountain View, CA)
Ladarixin		Compartmented pharmaceutical dosage forms	Triastek, Inc. (Nanjing, CN)
Ladarixin		Soluble C5aR antagonists	ChemoCentryx, Inc. (Mountain View, CA)
Ladarixin		Method for treating cancer using dual antagonists of CXCR1 and CXCR2	Syntrix Biosystems Inc. (Auburn, WA)

International Patents for Ladarixin

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Ladarixin	Australia	AU2017261372	2036-05-05
Ladarixin	Canada	CA3023278	2036-05-05
Ladarixin	China	CN107847398	2036-05-05
Ladarixin	European Patent Office	EP3452003	2036-05-05
Ladarixin	Hong Kong	HK1249728	2036-05-05
Ladarixin	Japan	JP2019520866	2036-05-05